Ladarixin
As of the edition of 20 October 2026, Ladarixin is a small molecule: stopped in 2026; acts on CXCR1 and CXCR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 9, 6 stopped early
- Disease areas
- Immune system; Hormones; Nutrition and metabolism; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Ladarixin.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 7 | 1 | 0 | 6 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Dompé Farmaceutici | Lead sponsor of trials | 2012 to now |